US 11,896,627 B2
Bacteria engineered to treat metabolic diseases
Dean Falb, Sherborn, MA (US); Vincent M. Isabella, Medford, MA (US); Jonathan W. Kotula, Berkeley, CA (US); Paul F. Miller, Salem, CT (US); Sarah Elizabeth Rowe, Durham, NC (US); Yves Millet, Newton, MA (US); and Adam B. Fisher, Cambridge, MA (US)
Assigned to Synlogic Operating Company, Inc., Cambridge, MA (US)
Filed by Synlogic Operating Company, Inc., Cambridge, MA (US)
Filed on Jan. 26, 2022, as Appl. No. 17/584,956.
Application 17/584,956 is a continuation of application No. 15/738,174, granted, now 11,291,693, previously published as PCT/US2016/039444, filed on Jun. 24, 2016.
Application 15/738,174 is a continuation in part of application No. PCT/US2016/032565, filed on May 13, 2016.
Claims priority of provisional application 62/354,681, filed on Jun. 24, 2016.
Claims priority of provisional application 62/354,682, filed on Jun. 24, 2016.
Claims priority of provisional application 62/348,416, filed on Jun. 10, 2016.
Claims priority of provisional application 62/348,620, filed on Jun. 10, 2016.
Claims priority of provisional application 62/347,508, filed on Jun. 8, 2016.
Claims priority of provisional application 62/347,576, filed on Jun. 8, 2016.
Claims priority of provisional application 62/347,554, filed on Jun. 8, 2016.
Claims priority of provisional application 62/336,012, filed on May 13, 2016.
Claims priority of provisional application 62/293,695, filed on Feb. 10, 2016.
Claims priority of provisional application 62/277,346, filed on Jan. 11, 2016.
Claims priority of provisional application 62/184,777, filed on Jun. 25, 2015.
Prior Publication US 2022/0226395 A1, Jul. 21, 2022
Int. Cl. A61K 35/74 (2015.01); A23L 33/135 (2016.01); A61P 3/10 (2006.01); A61K 9/00 (2006.01); A61K 35/741 (2015.01); C12N 15/52 (2006.01); A61K 35/747 (2015.01); A61K 35/744 (2015.01); A61K 35/745 (2015.01); A61K 35/00 (2006.01)
CPC A61K 35/74 (2013.01) [A23L 33/135 (2016.08); A61K 9/0053 (2013.01); A61K 35/741 (2013.01); A61K 35/744 (2013.01); A61K 35/745 (2013.01); A61K 35/747 (2013.01); A61P 3/10 (2018.01); C12N 15/52 (2013.01); A23V 2002/00 (2013.01); A61K 9/0031 (2013.01); A61K 2035/115 (2013.01); Y02A 50/30 (2018.01)] 22 Claims
OG exemplary drawing
 
1. A bacterium comprising a gene cassette that encodes a biosynthetic pathway for producing a short chain fatty acid, wherein the short chain fatty acid is butyrate, propionate, or acetate, and wherein the gene cassette is operably linked to a promoter that is induced by exogenous environmental conditions found in a mammalian gut and that is not associated with the gene cassette in nature, and wherein the bacterium further comprises a gene or gene cassette for producing indole-3-acetaldehyde.